<DOC>
	<DOCNO>NCT00056641</DOCNO>
	<brief_summary>This open-label , randomize , parallel group pharmacokinetics trial tipranavir/ritonavir ( TPV/RTV ) , alone combination RTV-boosted saquinavir ( SQV ) , amprenavir ( APV ) lopinavir ( LPV ) , plus optimized background regimen , multiple antiretroviral ( ARV ) experience HIV-1 patient . The primary objective determine safety pharmacokinetics : TPV/RTV give optimize background regimen ( OBR ) TPV/RTV give combination saquinavir , amprenavir , KaletraÂ® optimize background regimen ( OBR ) .</brief_summary>
	<brief_title>Dual Boosted - Protease Inhibitor ( PI ) Pharmacokinetics ( PK ) Trial ( Tipranavir / Ritonavir ) Highly Treatment-experienced HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>